← Eichor
Study identifier: NCT07008716 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Omitting CTV for Primary Tumor in LS-SCLC

Condition: SCLC, Limited Stage · Radiation Exposure · Radiotherapy Side Effect  ·  Sponsor: Sun Yat-sen University

PhasePhase 3
Planned participants852
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This randomized controlled non-inferior trial prospectively enrolled patients with limited-stage small cell lung cancer (LS-SCLC). Patients in the experimental group would receive radiotherapy with omission of the clinical target volume (CTV) for the primary tumor, while those in the control group would receive radiotherapy including CTV. The efficacy and toxicity of the two groups are compared to provide evidence for the radiotherapy of LS-SCLC. The target volume of LS-SCLC may be reduced by omitting CTV without increasing local recurrence but potentially reducing the dose to organs at risk and the side effects.

This description comes directly from the study's public registry record.

Talk to the study team

Ming Chen  ·  86+02087343504  ·  chenming@sysucc.org.cn

Always discuss trial participation with your own doctor first.

Locations (2)

Sun Yat-sen University Cancer CenterGuangzhou, Guangdong, ChinaRecruiting
Zhejiang Provincial Cancer HospitalHangzhou, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07008716